Nasopharyngeal Diseases  >>  fosaprepitant  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
fosaprepitant / Generic mfg.
NCT00895245: Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

Terminated
2
6
US
fosaprepitant dimeglumine, cisplatin, CACP, CDDP, CPDD, DDP, Neoplatin, palonosetron hydrochloride, Aloxi, RS 25259-197, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, Decaspray, DM, DXM, Functional Living Index-Emesis Questionnaire, Emesis Diary, Radiotherapy, 3-D conformal radiotherapy or IMRT
University of Washington, National Cancer Institute (NCI)
Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
09/10
02/11

Download Options